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A B S T R A C T
Background
Mucopolysaccharidosis type VI or Maroteaux-Lamy syndrome is a rare genetic disorder caused by the deficiency of arylsulphatase B.
The resultant accumulation of dermatan sulphate causes lysosomal damage.
The clinical symptoms are related to skeletal dysplasia (i.e. short stature and degenerative joint disease). Other manifestations include
cardiac disease, impaired pulmonary function, ophthalmological complications, hepatosplenomegaly, sinusitis, otitis, hearing loss and
sleep apnea. Intellectual impairment is generally absent. Clinical manifestation is typically by two or three years of age; however, slowly
progressive cases may not present until adulthood.
Enzyme replacement therapy with galsulfase is considered a new approach for treating mucopolysaccharidosis type VI.
Objectives
To evaluate the effectiveness and safety of treating mucopolysaccharidosis VI by enzyme replacement therapy with galsulfase compared
to other interventions, placebo or no intervention.
Search methods
Eletronic searches were performed on the Cystic Fibrosis and Genetic Disorders Group’s Inborn Errors of Metabolism Trials Register,
in CENTRAL, MEDLINE, LILACS, the Journal of Inherited Metabolic Disease and ClinicalTrials.gov.
Date of the last search of the Cystic Fibrosis and Genetic Disorders Group’s Inborn Errors of Metabolism Trials Register: 05 February
2016.
Selection criteria
Randomized and quasi-randomized controlled clinical studies of enzyme replacement therapy with galsulfase compared to other
interventions or placebo.
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Data collection and analysis
Two authors independently screened the studies, assessed the risk of bias and extracted data.
Main results
One study was included involving 39 participants who received either enzyme replacement therapy with galsulfase (recombinant human
arylsulphatase B) or placebo. This small study was considered to be of overall unclear quality, since the authors did not report how both
the allocation generation and concealment were performed.
The key finding at 24 weeks in the 12-minute walk test was a statistically significant mean difference of 92.00 meters between the
two groups in favour of the galsulfase group (95% confidence interval 11.00 to 172.00). While week 24 results for the three-minute
stair climb demonstrated some improvement in the treatment group as compared to the placebo group, this was not significant, mean
difference 5.70 (95% confidence interval -0.10 to 11.50).
A significant decrease in the urinary glycosaminoglycan levels was observed in favour of the galsulfase group at 24 weeks, mean difference
-227.00 (95% confidence interval -264.00 to -190.00).
In general, the dose of galsulfase was well tolerated and there were no significant differences in relation to adverse events. These events
include drug-related adverse events, serious and severe adverse events, those during infusion, drug-related adverse events during infusion,
and deaths. More infusion-related reactions were observed in the galsulfase group and were managed with interruption or slowing of
infusion rate or administration of antihistamines or corticosteroids drugs. No deaths occurred during the study.
Authors’ conclusions
The results of one small study (based on 24-week randomised phase of the study and prior to the open-label extension) demonstrated
that galsulfase is more effective than placebo in people with MPS VI, with significant improvements in the 12-minute walk test and a
reduction in urinary glycosaminoglycans.
There were no significant changes in cardiac or pulmonary functions, liver or spleen volume, overnight apnea-hypopnea, height and
weight, quality of life and adverse effects.
Further studies are needed to obtain more information on the long-term effectiveness and safety of enzyme replacement therapy with
galsulfase.
P L A I N L A N G U A G E S U M M A R Y
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Review question
We reviewed the evidence about the effectiveness and safety of treating mucopolysaccharidosis type VI by enzyme replacement therapy
with galsulfase (a manufactured version of the enzyme arylsulphatase B) compared to other interventions, no intervention or placebo.
Background
Mucopolysaccharidosis type VI is a rare genetic disorder where there is a lack of the enzyme arylsulphatase B. It is a progressive and
life-limiting condition with a range of symptoms, which may include coarse facial features, reduced joint mobility, short stature and
problems with the eyes, lungs and heart.
Prior to enzyme replacement therapy, only symptoms could be treated and not the underlying condition. Treatment with enzyme
replacement therapy has allowed the missing enzyme to be replaced with the aim to reduce the effects of the disease and prevent it
progressing.
Search date
The evidence is current to: 05 February 2016.
Study characteristics
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The review includes one study with 39 people with mucopolysaccharidosis type VI aged between five and 20 years old. The study
compared galsulfase to placebo (a substance which contains no medication) and people were selected for one treatment or the other
randomly. The study lasted for 24 weeks (with an open-label extension period of an additional 24 weeks).
Key results
Given that there is only one small study included, the evidence for this treatment is limited. The included study showed that motor
function improved in people who had received galsulfase, especially in their ability to walk. There was also an improvement in the
results of urine tests, which showed lower levels of the chemicals associated with MPS VI (glycosaminoglycan levels). These results were
seen in a short study and may reflect only short-term effects. There were no significant differences between treatment with galsulfase
and placebo in relation to adverse effects.
More research is required to study the long-term effects on heart and lung function, quality of life and survival.
Quality of the evidence
The methods of the study design were not clearly described and the impact of this on possible bias is unclear.
B A C K G R O U N D
A glossary of terms is available (Appendix 1).
Description of the condition
Mucopolysaccharidosis type VI (MPS VI), also known as
Maroteaux-Lamy syndrome, is an autosomal recessive disease. It
is caused by deficiency of N- acetylgalactosamine 4-sulphatase
(arylsulphatase B). This results in a cascade of problems includ-
ing lysosomal damage and accumulation of dermatan sulphate
(Cardoso-Santos 2008; Maroteaux 1963). It has been estimated
that approximately 1 in 340,000 births are affected with MPS VI
(Lowry 1990; Meikle 1999; Nelson 1997; Pinto 2004).
The clinical presentation varies based on age of onset and rate
of disease progression. The speed and intensity of damage caused
by the disease varies between the slowly and rapidly progress-
ing forms. Short stature and degenerative joint disease are con-
sequences of the skeletal dysplasia. Other clinical manifestations
include cardiac valve disease, reduction in pulmonary function,
hepatosplenomegaly, sinusitis, otitis, hearing loss, sleep apnea,
corneal clouding, inguinal or umbilical hernia and carpal tun-
nel disease. Intellectual impairment is generally absent (Giugliani
2007; Valayannopoulos 2010).
Clinical treatment of MPS VI has been based on improving some
of the most dangerous and debilitating manifestations of the dis-
ease (i.e. continuous positive airway pressure (CPAP) for sleep
apnea). Currently, palliative treatment still has a role, along with
other treatment options, such as bone marrow or hematopoi-
etic stem cell transplantation (HSCT) and enzyme replacement
therapy (ERT) (Giugliani 2007; Neufeld 2001; Valayannopoulos
2010).
The main indication of HSCT is for people with cognitive im-
pairment (i.e. severe form of MPS I) and has been recommended
in rare cases of MPS VI. Despite of the improvements of leukocyte
arylsulphatase B and urinary glycosaminoglycans levels, no impact
in skeletal abnormalities were observed in the long-term follow-
up case studies (Valayannopoulos 2010). In MPS VI it has been
considered a secondary option since the risks of the procedure do
not appear to exceed the benefits (Giugliani 2007).
Description of the intervention
Galsulfase is an enzymemanufactured by recombinant DNA tech-
nology that uses a mannose-6-phosphate receptor to bind to the
cell surface, transporting the enzyme into the lysosomes, in order
to supply arylsulphatase B (Valayannopoulos 2010).
Enzyme replacement therapy with galsulfase is currently recom-
mended as weekly intravenous infusions, delivered over a period
of four hours, at a recommended dose of 1 mg/kg body weight.
Adverse reactions have been observed typically being anaphylac-
tic. Reaction symptoms include dyspnea, rigours, nausea, chest
pain, pyrexia, exanthem, urticaria, abdominal pain and swelling.
Infusion-related reactions can be managed by the use of antihis-
tamines or steroids (with or without antipyretics) prior to infusion
(Giugliani 2007).
How the intervention might work
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Galsulfase treatment aims to replace the deficient arylsulphatase
B and thus limit, stop or reverse disease progression and improve
symptoms related to endurance and pulmonary function (Decker
2010). Due to poor skeletal vascularisation and the presence of
the blood-brain barrier it is less effective for treating skeletal and
central nervous system features (Giugliani 2007).
Why it is important to do this review
Even thoughmost experts recommendERTas first-line treatment,
most nations do not have an established public health policy that
considers ERT for the management of MPS VI, especially due to
the high costs of the treatment (Giugliani 2007). This review may
be used to help decision- and policymakers.
O B J E C T I V E S
To evaluate the effectiveness and safety of treatingMPSVI by ERT
with galsulfase compared to other interventions, no intervention
or placebo.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized controlled clinical studies.
Types of participants
Individuals with MPS VI of any age and any degree of disease
severity.Diagnosis should be established by enzyme assay in leuko-
cytes, fibroblasts or plasma or genetic mutation results.
Types of interventions
Enzyme replacement therapy with galsulfase at any dose for a
period of at least one month compared to other interventions,
placebo, or no intervention.
Types of outcome measures
Primary outcomes
1. Functional test
i) 12-minute walk test (12MWT)
ii) 3-minute stair climb (3MSC)
iii) other validated measures of functionality used by trial
authors (i.e. 6-minute walk test (6MWT))
Secondary outcomes
1. Lung function
i) forced expiratory volume at one second (FEV1)
ii) forced vital capacity (FVC)
iii) total lung capacity (TLC)
2. Cardiac function (assessed by echocardiography)
3. Change in urinary excretion of glycosaminoglycans (GAGs)
4. Z scores for height and weight
5. Overnight apnea-hypopnea index (AHI)
6. Quality of life (using a validated scoring system, e.g. SF-36)
7. Joint mobility (using a validated scoring system, e.g. Joint
Range of Motion (JROM), grip and pinch strength tests)
8. Liver and spleen volume (measured by ultrasound or
computed tomography (CT) scan of the abdomen)
9. Audiology assessment (using a validated scoring system, e.g.
Pure-Tone Testing, auditory brainstem response (ABR),
otoacoustic emissions (OAEs))
10. Adverse effects and toxicity of treatment
Search methods for identification of studies
Electronic searches
Relevant trialswere identified by searching theCochraneCystic Fi-
brosis andGeneticDisordersGroup’s InbornErrors ofMetabolism
Trials Register using the term: mucopolysaccharidosis.
The Cochrane Cystic Fibrosis and Genetic Disorders Group’s In-
born Errors ofMetabolism Trials Register was compiled from elec-
tronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of The Cochrane
Library), weekly searches of MEDLINE, LILACS database and
the prospective handsearching of one journal - Journal of Inherited
Metabolic Disease. Unpublished work were identified by searching
through the abstract books of the Society for the Study of Inborn
Errors of Metabolism conference and the SHS Inborn Error Re-
view Series. For full details of all searching activities for the register,
please see the relevant section of the Cystic Fibrosis and Genetic
Disorders Group Module.
Date of last search: 05 February 2016.
We also undertook additional searches of the Cochrane Central
Register of Controlled Trials (CENTRAL), PubMed, LILACS (
http://lilacs.bvsalud.org/) (Appendix 2; Appendix 3; Appendix 4)
and ClinicalTrials.gov (http://www.clinicaltrials.gov).
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Searching other resources
We scrutinized the reference lists of any identified relevant studies
for additional citations and contacted specialists in the field, first
authors of the included study and pharmaceutical manufacturers
for any relevant unpublished data.
Data collection and analysis
Selection of studies
One author verified all identified reports and extracted the relevant
information and data. To ensure reliability of the selection of stud-
ies, one of the remaining authors independently re-verified these
reports. If any disagreement or doubts occurred, we discussed this
until consensus was reached.
Data extraction and management
Two authors independently extracted all data. We resolved differ-
ences by discussion and if necessary, we contacted the study au-
thors to resolve any outstanding issues. We identified exclusions
and dropouts. If any relevant information or data were not avail-
able (even with the study authors’ feedback), we identified these
as missing data. We entered the data into the Review Manager
software (RevMan 2014).
Assessment of risk of bias in included studies
Two authors independently evaluated the selected studies using
the recommendations as described in theCochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We expressed
the domains below simply as having either a low, high or unclear
risk of bias:
1. random sequence generation;
2. concealment of allocation;
3. blinding of: participants, personnel, outcome assessment;
4. incomplete outcome data;
5. selective reporting;
6. other potential sources of bias.
Measures of treatment effect
We calculated treatment effects using the risk ratio (RR) with 95%
confidence intervals (CIs) for dichotomous data.
For continuous outcomes, we estimated themean difference (MD)
and 95% CIs. We used the generic inverse variance method
(GIVM) for this type of outcome in the studies that only reported
odds ratios or relative risks and standard errors (SEs).
Unit of analysis issues
We did not identify studies with a cross-over design. In future up-
dates, we intend to follow the recommendations of Elbourne, un-
dertaking a paired analysis, using a t-test in data obtained by each
participant and comparing the treatment interventions (Elbourne
2002). For cluster-randomised studies, in the analyses, if possible,
we will attempt to account for any unit of analysis error, consider-
ing the methods described in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011) by using an estimate
of the intra-cluster correlation co-efficient (ICC) derived from the
study (if possible), from a similar study or from a study of a similar
population.
Dealing with missing data
In the case of absent data or queries about missing data, the first
author (MJB) contacted the study authors.
Assessment of heterogeneity
We did not evaluate the heterogeneity, because we identified only
one study. In future updates, the clinical heterogeneity of the stud-
ies will be quantified using the Chi2 test and the I2 statistic to
illustrate the percentage of the variability in effect estimates re-
sulting from heterogeneity rather than sampling error (Higgins
2003), where I2 values may indicate, as follows:
0% to 40%: might not be important;
30% to 60%: may represent moderate heterogeneity;
50% to 90%: may represent substantial heterogeneity;
75% to 100%: considerable heterogeneity.
Assessment of reporting biases
In future updates, we intend to build a funnel plot if there are a
sufficient number of studies (i.e. 10). If the funnel plot is asym-
metrical, this may indicate publication bias. However, there are
other reasons for asymmetry including heterogeneity, outcome re-
porting bias and small study effects.
Data synthesis
Weused the fixed-effectmodel formeta-analysis of data. For future
updates, we will consider using a random-effects model should
there be substantial heterogeneity between the studies.
Subgroup analysis and investigation of heterogeneity
In future updates, if further studies are added and we identify
heterogeneity between them, we intend to undertake subgroup
analyses according to:
1. disease progression (slowly and rapidly advancing forms)
and;
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2. enzyme dose.
Sensitivity analysis
Sensitivity analyses were not carried out as only a single study was
identified. In future updates, if there are a sufficient number of
eligible studies included (10 or more), we will undertake a sensi-
tivity analysis to assess the robustness of the results. For this eval-
uation we considered the risk of bias for: allocation concealment;
method of blinding; rates of withdrawal for each outcome; other
study design (Deeks 2011). We aim to perform a sensitivity analy-
sis by considering studies with a high risk of bias in these domains
against those with a low or unclear risk of bias.
R E S U L T S
Description of studies
See: Characteristics of included studies ; Characteristics of
excluded studies.
Results of the search
A total of 295 references were identified through the search strate-
gies, of which 289 were excluded (i.e. did not the meet inclu-
sion criteria or were duplicate references). Full texts of six stud-
ies were obtained for further assessment. After a detailed reading,
five studies were excluded (see Characteristics of excluded studies)
(Bagewadi 2008; Harmatz 2004; Harmatz 2005; Harmatz 2013;
Pitz 2009). Only one study (six references) was included in this
review. Refer to the flow diagram for the details of the search pro-
cess (Figure 1).
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Figure 1. Study flow diagram.
7Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
One study met the inclusion criteria of this review (Harmatz
2006).
Design
The selected study was a phase III, randomized, multicenter,
placebo-controlled, double-blind study and evaluated the effi-
cacy and safety of galsulfase in people with MPS VI (Harmatz
2006). A 24-week open-label extension to the study was con-
ducted and all participants receivingplacebo solution in the first 24
weeks commenced treatment with recombinant human N-acetyl-
galactosamine 4-sulfatase (recombinant human arylsulphatase B)
(rhASB) solution. As this phase was not re-randomised the results
are not included in the review.
Sample sizes
A total of 39 participants were included (Harmatz 2006).
Setting
Participants were enrolled at six clinical sites, but no further details
were provided (Harmatz 2006).
Participants
The 39 participants were over seven years of age with either bio-
chemical or genetic proof ofMPSVI, with the ability towalkwith-
out assistance at least five meters and no more than 270 meters in
the first six minutes, or no more than 400 meters in a 12-minute
walk test. Exclusion criteria were clinically significant spinal cord
compression, amedical conditionor other circumstance that could
interfere with study compliance.
Participants were randomised into two groups: 19 in the rhASB
group (7 males and 12 females, mean age 13.7 years); 20 in the
placebo group (six males and 14 females, mean age 10.7 years).
Interventions
Participants were randomised to receive intravenous infusions of
rhASB1.0mg/kg or a placebo solution over 24weeks administered
over four hours once weekly with 2.5% of the total dose infused
during the first hour and the remainder over the next three hours
(Harmatz 2006). A pre-medication with either diphenhydramine
0.5 mg/kg or promethazine 0.15 mg/kg was administrated to all
participants.
Outcomes
The study considered the following outcomes:
1. 12MWT;
2. 3MSC,
3. Level of urinary GAG excretion;
4. Others outcomes analysed:
i) assessments of joint pain, joint stiffness, and physical
energy level;
ii) assessment of joint ROM;
iii) assessment of hand dexterity as evidenced by the
number of coins picked up in one minute;
iv) clinical parameters including pulmonary and cardiac,
and ophthalmologic monitoring tests.
Safety was determined by considering adverse events, monitoring
of changes in laboratory parameters (chemistry, hematology, uri-
nalysis, thyroid function) and assessment of electrocardiography
(Harmatz 2006).
Excluded studies
See Characteristics of excluded studies table.
We excluded five studies because they did not meet the inclu-
sion criteria. The Harmatz 2004 and 2005 studies were phase I/
II and phase II clinical studies, respectively (we did not consider
studies that evaluated safety and dosing requirements) (Harmatz
2004; Harmatz 2005); two publications were case-series studies
(Bagewadi 2008; Pitz 2009); and one was an evaluation of the effi-
cacy and safety of two dosing regimens of the intervention without
a control group (Harmatz 2013).
Risk of bias in included studies
See the ’Risk of bias’ summary (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Genration of the randomisation sequence
The study was described as randomised, but the method of ran-
domisation was not provided. We have classified this domain as
having an unclear risk of bias.
Allocation concealment
No description of allocation concealment was reported, we have
therefore classified this domain as having an unclear risk of bias.
Blinding
The study stated that investigators and staff were not informed of
the original treatment assignments and did not participate in the
efficacy assessments. We classified this domain as having a low risk
of bias.
Incomplete outcome data
The study reported that safety analyses included all participants
who received at least one dose of the intervention and the efficacy
analyses included all randomised participants (intention-to-treat
analysis). The trial author also declared that 11 individuals, who
did not fulfil inclusion criteria (seven exceeded the walk distance
eligibility entry criteria at screening, three were under seven years
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of age, and one had experienced a failed bone marrow transplant
11 years earlier) were not excluded (did not interfere with study
compliance) and were also randomised. Authors mentioned that
one participant withdrew from the study after four infusions of
placebo for reasons unrelated to treatment. We considered this
domain as having a low risk of bias.
Selective reporting
The study only presented the results for the following outcomes:
12MWT; 3MSC; level of urinary GAG excretion; and pulmonary
function. Results of others outcomes analysed (joint pain, hand
dexterity and cardiac and ophthalmologic parameters) were not
provided and authors only declared that rhASB had no effect in
these endpoints. We considered this domain as having an unclear
risk of bias.
Other potential sources of bias
Despite randomization, the characteristics of the study partici-
pants were not similar between the two groups (participants in the
placebo group were, on average, younger, shorter, and weighed less
than those in the rhASB group, the authors declared that none of
these differences was statistically significant). No other potential
sources of bias were detected. We considered this domain as hav-
ing an unclear risk of bias.
Effects of interventions
Primary outcomes
1. Functional test
a. 12-minute walk test (12MWT)
This was reported in the included study, where the intervention
group had a substantial increase in walk distance during the first
six weeks of treatment, with a sustained, stable improvement that
remained the same between week 18 and week 24. At the end
of the randomisation period (24 weeks), the intervention group
demonstrated significant improvement, compared to placebo with
a MD of 92.00 meters (95% CI 12.00 to 172.00) in the change
from baseline; P = 0.03 (Analysis 1.1; Figure 3).
Figure 3. Forest plot of comparison: 1 Galsulfase verus placebo, outcome: 1.1 12MWT.
b. 3-minute stair climb (3MSC)
At week 24, the study authors reported a greater improvement in
the treatment group than in placebo; however, when entered into
our analysis, while the results in the rhASB group demonstrated
some improvement compared to the placebo group in a longitu-
dinal analysis, this was not significant, MD 5.70 (95% CI -0.10
to 11.50); P = 0.062. (Analysis 1.2; Figure 4).
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Figure 4. Forest plot of comparison: 1 Galsulfase verus placebo, outcome: 1.2 3MSC.
c. Other validated measures of functionality
The 6MWT was not considered as an endpoint of the included
study (Harmatz 2006). However, the authors reported that the
rhASB group was superior to the placebo group in distance walked
at the 6-minute time point during the 12MWT test, with a MD
of 53.00 meters at week 24 (95% CI 16.00 to 90.00), considering
this as supportive of the primary endpoint; P = 0.007 (Analysis
1.3; Figure 5).
Figure 5. Forest plot of comparison: 1 Galsulfase verus placebo, outcome: 1.3 6MWT.
Secondary outcomes
1. Lung function
a. forced expiratory volume at one second (FEV1)
It was reported in the primary paper that there was no difference
in FEV1 during the study, but no data or P values were reported
(Harmatz 2006).
b. forced vital capacity (FVC)
No improvement of FVC was observed (Harmatz 2006). There
was no significant difference in the absolute change in FVC at
week 24 for the rhASB group, MD -0.01 (95% CI -0.08 to 0.06)
(Analysis 1.4).
c. total lung capacity (TLC)
This outcome was not reported.
d. maximum voluntary ventilation (MVV)
This parameter was evaluated to determine any improvement in
rib-cage excursion as a result of improved flexibility or increased
strength (Harmatz 2006). The results were not statistically signif-
icant, MD 1.90 (95%CI -2.05 to 5.85) (Analysis 1.4).
2. Cardiac function
This outcome was not reported (Harmatz 2006).
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3. Change in glycosaminoglycans (GAGs) urinary excretion
The results showed a significant difference in favour of the rhASB
group at week 24, MD -227.00 (95% CI -264.00 to -190.00)
(Harmatz 2006) (Analysis 1.5).
4. Z scores for height and weight
This outcome was not reported (Harmatz 2006).
5. Overnight apnea-hypopnea index (AHI)
This outcome was not reported (Harmatz 2006).
6. Quality of life
This outcome was not reported (Harmatz 2006).
7. Joint mobility
It was reported in the primary paper that there was no difference
in joint mobility during the study, but no data or P values were
reported (Harmatz 2006).
8. Liver and spleen volume
This outcome was not reported Harmatz 2006).
9. Audiology assessment
This outcome was not reported Harmatz 2006).
10. Adverse effects and toxicity of treatment:
At week 24 adverse events were divided into the following subcat-
egories (Harmatz 2006) (Analysis 1.6; Figure 6). There were no
significant differences observed for:
Figure 6. Forest plot of comparison: 1 Galsulfase verus placebo, outcome: 1.6 Adverse events.
• deaths: nil in either group;
• drug-related adverse events, RR 1.93 (95% CI 0.89 to
4.17);
• serious adverse events, RR 0.79 (95% CI 0.20 to 3.07);
• severe adverse events, RR 1.05 (95% CI 0.31 to 3.62);
• adverse events during infusion, RR 1.45 (95%CI 0.75 to
2.80);
• drug-related adverse events during infusion, RR 2.63 (95%
CI 0.99 to 6.98).
More infusion-related reactions occurred in the rhASB group.
These were easily managed with interruption or slowing of in-
fusion rate or administration of an extra-dose of antihistamines
or corticosteroids. Other adverse effects were similar in both
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groups (i.e. rigours, pyrexia, chest pain, dyspnea, abdominal pain,
headache) and were most likely related to the diphenhydramine
premedication and the participant’s poor respiratory status.
D I S C U S S I O N
Summary of main results
The results of the Harmatz study showed some benefits in those
treated with recombinant human arylsulphatase B (rhASB) (gal-
sulfase) in comparison to those who received placebo (Harmatz
2006). It is important to realize that the characteristics of the study
participants were not similar between the two groups (partici-
pants in the placebo group were, on average, younger, shorter, and
weighed less than those in the rhASB group, the authors declared
that none of these differences was statistically significant).
There was significant improvement in the 12-minute walk test
(12MWT) in the rhASB group as compared to placebo based
on the longitudinal analysis, mean difference (MD) 92.00 meters
(95% confidence interval (CI) 12.00 to 172.00). Although the
study has not considered the 6-minute walk test (6MWT) as an
endpoint, an analysis at week 24 was described as supportive of
the 12MWT results, showing significant differences in this time
point (6 minutes) by 53 meters (95% CI 16.00 to 90.00).
While the 3-minute stair climb (3MSC) test did not show sta-
tistically significant improvement, the results were better in the
rhASB group as compared to the placebo group, MD 5.70 (95%
CI -0.10, 11.50).
Pulmonary function was evaluated in long-term enzyme replace-
ment therapy (ERT) treatment with rhASB. Pulmonary tests, such
as forced vital capacity (FVC), forced expiratory volume at one
second (FEV1) and in a subset of participants, maximum volun-
tary ventilation (MVV), were analysed. During the 24 weeks of
the randomised period, FVC, FEV1 and MVV showed no signif-
icant differences from baseline.
A reduction of 75% from baseline in glycosaminoglycans (GAG)
levels were observed at week 24 in the rhASB group. This was
maintained between week 25 and week 48 (in the open-label ex-
tension phase of the study), with all participants experiencing a
similar decrease.
The Harmatz study reported no data for other tertiary endpoints
(assessments of joint pain, joint stiffness, physical energy level
and clinical parameters such as ophthalmologic monitoring tests).
The authors stated there did not appear to be any difference of
effect between groups, but did not publish the participants’ results,
indicating a potential ’reporting bias’.
In general, treatmentwith rhASBwaswell tolerated by participants
during the 24 weeks of the randomised study. All but one of the
participants in the study developed IgG antibody to rhASB after
24 weeks of drug infusion.
Overall completeness and applicability of
evidence
The evidence for the efficacy of ERT with rhASB is limited given
there is only one relevant study that provided data on the short-
term efficacy and safety of this treatment. The study did, how-
ever, highlight significant improvements in the 12MWT (and
the 6MWT as a supportive outcome) and urinary GAG levels
(Harmatz 2006). Support for improvement in endurance was also
seen with the results of the 3MSC, although these results were not
clinically significant.
Quality of the evidence
The included study was considered to be of unclear quality, since
the authors did not report how both the allocation generation
and concealment were performed. Furthermore, the number of
participants included was small and the follow-up time was short.
Important outcomeswere not determined, e.g. respiratory capacity
and cardiac function, quality of life and mortality.
Potential biases in the review process
We followed the criteria listed within the ’Assessment of risk of
bias’ section to ensure the risk of bias was minimized during trial
selection.
Agreements and disagreements with other
studies or reviews
Other non-randomized studies evaluating the ERTwith galsulfase
are available. Due to the safety of the drug, Bagewadi suggested
home ERT with galsulfase, although, a detailed management plan
for potential anaphylaxis and infusion-associated reaction (IAR)
has to be adopted (Bagewadi 2008). Close monitoring is required
during infusions in those with a history of IAR, especially given
most people with MPS VI have cardiac and respiratory system
impairment. Dogan reported the first case of an individual with
MPS VI who developed thrombocytopenia after the third dose of
therapy, to share their approach for this case (Dogan 2011).
Braunlin evaluated cardiac function (Braunlin 2013).Clinical data
were pooled from the phase I, phase I/II and phase III trials and
analysed considering participants for whom data were available at
all three study points (baseline, weeks 48 and 96, not including
the randomised period) of galsulfase treatment. In spite of long-
term enzyme therapy, cardiac valve stenosis and hypertrophy did
not change in all individuals.
Between 2001 and 2002 a cross-sectional survey study of 121 peo-
ple with MPS VI was conducted to establish demographics, uri-
nary GAG levels and clinical progression of the disease. In 2013,
a re-survey study was conducted to obtain repeat 10-year cross-
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sectional data on those individuals that took part in the survey
study (n = 59). A total of 55 individuals received galsulfase and
the mean (standard deviation) treatment duration was 6.8 (2.2)
years between baseline to follow up. Long-term patients treated
with galsulfase were associated with improvements in pulmonary
function and endurance. The 6MWT was considered to deter-
mine endurance, mobility and also to provide an indication of
cardiopulmonary health. Those treated with galsulfase who com-
pleted the test had an improvement of 65.7minutes at follow up
compared to baseline (P<0.0001). The levels of uGAG decreased
by 87.9% in the participants treated with galsulfase (n=55) versus
49.8% in the untreated group (n =3) at follow up compared to
baseline. Rates of overall mortality reduced among those treated
with galsulfase versus the untreated group (16.5% versus 50.0%;
unadjusted hazard ratio, 0.24 (95% CI 0.10 to 0.59) (Giugliani
2014). In general, these findings are aligned with the results from
Harmatz study and show consistent improvements on the main
outcomes in the long-term results of those treated with galsulfase
(Harmatz 2006).
A systematic review on the same topic was published in 2009 (El
Dib 2009). The authors declared to select and judge the litera-
ture using the recommendations of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). The employed
methodology was similar, except for the inclusion of phase I/II in
the review. Nevertheless, the authors could not perform a meta-
analysis of them because they did not consider the same doses
during the follow-up period. The criteria for data analysis that we
considered was also different.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Only one randomised controlled study (with an overall unclear
risk of bias) was included in this review and it failed to describe
important outcomes that correspond to patients’ vital functions,
such as cardiac and respiratory function, or z scores for height and
weight. Quality of life and mortality were not evaluated. Futher
studies are required to obtain evidence on long-term effectiveness
and safety of ERTwith galsulfase.
Implications for research
Further high quality studies need to be developed to look at: (i)
long-term effects of ERT; (ii) galsulfase use in younger people;
(iii) dose optimisation; and (iv) effect on cardiac and respiratory
function, growth, quality of life and mortality.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Harmatz 2006
Methods Phase III, randomised, multicenter, placebo-controlled, double-blind study with 24-
week extension period
Participants 39 participants with MPS VI.
Inclusion criteria was age > 7 years with biochemical or genetic confirmation of MPS
VI, ability to walk without assistance at least 5 meters and no more than 270 meters in
the first six minutes, or no more than 400 meters in 12 minutes, in a 12MWT.
Exclusion criteria were clinically significant spinal cord compression or a medical con-
dition or other circumstance that could interfere with study compliance.
Participants were randomised into 2 groups: 19 in rhASB group (7males and 12 females,
mean age 13.7 years); 20 participants in placebo group (6 males and 14 females, mean
age 10.7 years).
The length of the double-blind period was 24 weeks. An open-label 24-week extension
study was conducted and all patients receiving placebo solution in the first 24-weeks
were converted to receive rhASB solution
Interventions 1.0 mg/ml intravenous infusion of rhASB or placebo weekly.
Outcomes Primary outcomes:
12MWT
Secondary outcomes:
3MSC
Change in GAGs urinary excretion
Other outcomes included:
Lung function
Cardiac function
Joint mobility
Adverse effects
Notes Funding sources: the study was sponsored by BioMarin Pharmaceutical Inc., and it was
supported, in part, with funds provided by the National Center for Research Resources,
5 M01 RR-01271 (Dr Harmatz)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but the method
of randomisation was not described
Allocation concealment (selection bias) Unclear risk Description of allocation concealment was
not reported.
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Harmatz 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors reported that safety analyses
included all participants who received at
least one dose of intervention and the effi-
cacy analyses included all randomised par-
ticipants (intention-to-treat analysis). They
also declared that 11 randomised partici-
pants did not fulfil inclusion criteria (were
not excluded)
Selective reporting (reporting bias) Unclear risk The outcomes were as described in the
study protocol. The study did not show
data from any of the other outcomes in-
cluded, only declaring that rhASB had no
effect in these endpoints
Other bias Unclear risk Despite randomization, the characteristics
of the study participants were not similar
between the two groups (participants in the
placebo group were, on average, younger,
shorter, and weighed less than those in the
rhASB group, the authors declared that
none of these differences was statistically
significant). No other potential sources of
bias were detected
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study stated that investigators and staff
were not informed of the original treatment
assignments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study stated that investigators and staff
did not participate in the efficacy assess-
ments
3MSC: 3-minute stair climb
12MWT: 12-minute walk test
GAGs: glycosaminoglycans
rhASB: recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulphatase B)
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bagewadi 2008 Case series.
Harmatz 2004 Phase I/II study.
Harmatz 2005 Phase II study.
Harmatz 2013 Phase IV study without control group
Pitz 2009 Case series.
19Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Galsulfase verus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 12MWT 1 Mean Difference (Fixed, 95% CI) Totals not selected
1.1 at 24 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 3MSC 1 Mean Difference (Fixed, 95% CI) Totals not selected
2.1 at 24 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 6MWT 1 Mean Difference (Fixed, 95% CI) Totals not selected
3.1 at 24 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Respiratory tests 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 FVC 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 MVV 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 GAG Level 1 Mean Difference (Fixed, 95% CI) Totals not selected
5.1 at 24 weeks 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Deaths 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Drug-related AEs 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Serious AEs 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Severe AEs 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 AEs during infusion 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.6 Drug-related AEs during
infusion
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Galsulfase verus placebo, Outcome 1 12MWT.
Review: Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Comparison: 1 Galsulfase verus placebo
Outcome: 1 12MWT
Study or subgroup Galsulfase Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 weeks
Harmatz 2006 19 19 92 (40.8163) 92.00 [ 12.00, 172.00 ]
-200 -100 0 100 200
Favours placebo Favours galsulfase
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Analysis 1.2. Comparison 1 Galsulfase verus placebo, Outcome 2 3MSC.
Review: Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Comparison: 1 Galsulfase verus placebo
Outcome: 2 3MSC
Study or subgroup Galsulfase Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 weeks
Harmatz 2006 19 19 5.7 (2.95918) 5.70 [ -0.10, 11.50 ]
-10 -5 0 5 10
Favours placebo Favours galsulfase
Analysis 1.3. Comparison 1 Galsulfase verus placebo, Outcome 3 6MWT.
Review: Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Comparison: 1 Galsulfase verus placebo
Outcome: 3 6MWT
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 weeks
Harmatz 2006 53 (18.8776) 53.00 [ 16.00, 90.00 ]
-100 -50 0 50 100
Favours placebo Favours galsulfase
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Analysis 1.4. Comparison 1 Galsulfase verus placebo, Outcome 4 Respiratory tests.
Review: Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Comparison: 1 Galsulfase verus placebo
Outcome: 4 Respiratory tests
Study or subgroup Galsulfase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 FVC
Harmatz 2006 19 -0.02 (0.13) 18 -0.01 (0.08) -0.01 [ -0.08, 0.06 ]
2 MVV
Harmatz 2006 15 2.1 (6.3) 17 0.2 (4.9) 1.90 [ -2.05, 5.85 ]
-4 -2 0 2 4
Favours placebo Favours galsulfase
Analysis 1.5. Comparison 1 Galsulfase verus placebo, Outcome 5 GAG Level.
Review: Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Comparison: 1 Galsulfase verus placebo
Outcome: 5 GAG Level
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 at 24 weeks
Harmatz 2006 -227 (18.8775) -227.00 [ -264.00, -190.00 ]
-500 -250 0 250 500
Favours galsulfase Favours placebo
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Analysis 1.6. Comparison 1 Galsulfase verus placebo, Outcome 6 Adverse events.
Review: Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Comparison: 1 Galsulfase verus placebo
Outcome: 6 Adverse events
Study or subgroup Galsulfase Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Deaths
Harmatz 2006 0/19 0/20 Not estimable
2 Drug-related AEs
Harmatz 2006 11/19 6/20 1.93 [ 0.89, 4.17 ]
3 Serious AEs
Harmatz 2006 3/19 4/20 0.79 [ 0.20, 3.07 ]
4 Severe AEs
Harmatz 2006 4/19 4/20 1.05 [ 0.31, 3.62 ]
5 AEs during infusion
Harmatz 2006 11/19 8/20 1.45 [ 0.75, 2.80 ]
6 Drug-related AEs during infusion
Harmatz 2006 10/19 4/20 2.63 [ 0.99, 6.98 ]
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours galsulfase
A P P E N D I C E S
Appendix 1. Glossary
Term Explanation
Dysostosis multiplex Specific pattern of radiographic changes observed in many lysosomal storage
disorders
Hepatosplenomegaly Enlargement of the liver and spleen. It can occur as a result of infection, storage
disorders or malignancy
23Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Skeletal dysplasia Disorders in bone and cartilage development causing abnormalities of parts of
or the entire skeleton
Autosomal recessive One of several ways that a trait, disorder, or disease can be passed down through
families
Dermatan sulphate Also known as chondroitin sulphate B, is composed of linear polysaccharides
assembled as disaccharide units containing N-acetyl galactosamine
Hematopoietic stem cell transplantation (HSCT) Intravenous infusion of hematopoietic stem and progenitor cells to establish
marrow and immune function
Pyrexia Medical term for fever.
Exanthem Widespread rash usually accompanied by fever, malaise and headache
Urticaria Medical term for hives.
Appendix 2. CENTRAL search strategy
#1 Mucopolysaccharidosis VI
#2 Maroteaux-Lamy
#3 MPS VI
#4 “Mucopolysaccharidosis VI”[Mesh]
#5 #1 OR #2 OR #3 OR #4
#6 enzyme
#7 “Enzyme Replacement Therapy”[Mesh]
#8 #6 OR #7
#9 #5 AND #8
#10 randomised controlled trial [pt]
#11 controlled clinical trial [pt]
#12 randomised [tiab]
#13 placebo [tiab]
#14 drug therapy [sh]
#15 randomly [tiab]
#16 trial [tiab]
#17 groups [tiab]
#18 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#19 animals [mh] NOT humans [mh]
#20 #18 NOT #19
#21 #9 AND #20
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Appendix 3. MEDLINE search strategy
#1 Mucopolysaccharidosis VI
#2 Maroteaux-Lamy
#3 MPS VI
#4 “Mucopolysaccharidosis VI”[Mesh]
#5 #1 OR #2 OR #3 OR #4
#6 enzyme
#7 “Enzyme Replacement Therapy”[Mesh]
#8 #6 OR #7
#9 #5 AND #8
#10 randomised controlled trial [pt]
#11 controlled clinical trial [pt]
#12 randomised [tiab]
#13 placebo [tiab]
#14 drug therapy [sh]
#15 randomly [tiab]
#16 trial [tiab]
#17 groups [tiab]
#18 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#19 animals [mh] NOT humans [mh]
#20 #18 NOT #19
#21 #9 AND #20
Appendix 4. LILACS search strategy
Mh:“Mucopolysaccharidosis VI” or “Mucopolisacaridosis VI” or “Mucopolissacaridose VI” or “Polydystrophic Dwarfism” or
“Maroteaux-Lamy Syndrome” orMh:C16.320.565.202.715.670$ orMh:C16.320.565.595.600.670$ orMh:C17.300.550.575.670$
orMh:C18.452.648.202.715.670$ orMh:C18.452.648.595.600.670$ or “Mucopolysaccharidosis VI” or “Maroteaux Lamy” or “MPS
VI” or “Mucopolissacaridoses” and Mh: “Enzyme Replacement Therapy” or “Terapia de Reemplazo Enzimático” or “Terapia de
Reposição de Enzimas” or Mh:E02.319.353.500$ or Mh:“Enzymes” or “Enzimas” or “Enzimas” or Mh:D08.811$
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Due to cervical cord compression and myelopathy are recognised as features of the disease and were excluded from the outcome “adverse
effects and toxicity of treatment”.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Enzyme Replacement Therapy [∗methods]; Glycosaminoglycans [urine]; Mucopolysaccharidosis VI [∗drug therapy; urine]; N-Acetyl-
galactosamine-4-Sulfatase [∗therapeutic use]; Randomized Controlled Trials as Topic; Recombinant Proteins [therapeutic use]
MeSH check words
Humans
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